Implementing PAT, One Step at a Time

If FDA’s guidance and its risk-based inspection focus weren’t reason enough for pharma companies to implement Process Analytical Technology (PAT), its benefits in the areas of quality improvement, validation, manufacturing yield and efficiency, and reductions in inventory and overhead ought to spur increased adoption, urges Robert Cogdill, Ph.D., of Duquesne University's Center for Pharmaceutical Technology. Those who missed his presentation at Interphex last week can access it here.

By Robert Cogdill, Ph.D., Industrial Research Coordinator, Center for Pharmaceutical Technology, Duquesne University

Click the Download Now button below to access this 36-page (695 KB) PDF document.

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments